- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02637921
Planetary Habitat Simulation: Bone Metabolism Studies (PlanHab)
Planetary Habitat Simulation: The Combined Effects of Bed Rest and Normobaric Hypoxia Upon Bone and Mineral Metabolism (WP3)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The risk of bone loss in response to immobilization and space flight is widely recognized, with such bone losses occurring predominantly in the legs. Loading forces in the lower extremities are typically low in space and during bed rest, but musculoskeletal loading countermeasures can prevent or reduce bone losses induced in these conditions. Although the primary origin may be of a mechanical nature, bone losses in astronauts and immobilized patients are likely to be modulated by the endocrine and the internal environment.
Bone loss and osteoporosis is also prevalent in those with chronic obstructive pulmonary disease (COPD). The most discussed etiological factors for this condition include lack of physical activity, vitamin-D deficiency, hypogonadism, use of corticosteroids and smoking. However, COPD is associated with tissue hypoxemia and it is unclear whether hypoxia per se will affect bone turnover or metabolism.
The protocol of the current study standardises potential confounding factors, such as physical activity, ambient temperature, hypoxic stimulus and nutritional composition of the diet across all 3 interventions, and aims to extend our knowledge of the effects of hypoxia and bedrest on bone metabolism and phospho-calcic homeostasis.
Fourteen non-obese men, who are otherwise healthy, will be recruited following medical and psychological screening. They will be invited to attend the Olympic Sport Centre, Planica, Slovenia on 3 occasions, with each visit being 31 days in duration and separated by 5 months. Each 31-day visit ('campaign') includes a baseline recording period (5 days), 21 days of intervention, and a recovery period (5 days), with a follow-up visit being carried out 14 days after each intervention. The 3 interventions will be allocated in a randomized, cross over design: i) Normobaric normoxic bed rest (NBR; FiO2=21%), ii) Normobaric hypoxic ambulatory confinement (HAMB; FiO2=14%; ~4000 m simulated altitude), and iii) Normobaric hypoxic bed rest (HBR; FiO2=14%). A standardized, repeating, 14-day dietary menu, comprised of foods commonly consumed in the Slovenian diet, will be applied during all campaigns. Targeted energy intakes will be calculated individually using a modified Benedict-Harris formula, with physical activity factor multipliers of 1.2 for the HBR and NBR campaigns and 1.4 for the HAMB campaign, used to promote energy balance. Body mass will be monitored daily during the campaigns using a gurney incorporating load cells, and whole body composition will be determined before and immediately after each intervention using fan beam dual-emission X-ray absorptiometry. Macronutrient composition of the diet will be approximately 17% protein, 53% carbohydrate and 30% fat, with >1.1g of protein per kg body weight provided per day, and daily salt (sodium chloride) intake being <10g. Food will be provided in weighed portions and subjects will be encouraged to eat all food supplied. However, any food not eaten will be weighed and actual amount consumed recorded in a diet analysis programme.
Participants will have bone mineral content assessed at 5 time points (before, 3 during and one after each intervention) using pQCT scans of the calf and thigh. Horizontal scans will be taken at 4%, 14%, 38%, and 66% of the tibia (assessed from its distal end), and at 4% and 33% of the femur. Twenty-four hour urine collections will be obtained before (2 time points), during (11 time points) and after (3 time points) each intervention, and will be assessed for urinary calcium and phosphate content, and for a marker of bone reabsorption (N-terminal telopeptide). In addition, early morning, fasting venous blood samples will also be taken before (2 time points), and during (5 time points) each intervention. These will be analysed for calcium, phosphate, bone specific alkaline phosphatase, parathyroid hormone, 25-Hydroxyvitamin D, Procollagen-I-N-terminal propeptide and regulators of bone metabolism, (Dickkopf-related protein 1 and Sclerostin).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Physically and mentally healthy subjects
- Body mass index < 25 kg/m2
- Height 158 - 190 cm
- Waist circumference < 94 cm
- Volunteers that are able to declare their willingness to participate in the entire study
- Willing to be assigned randomly to the three groups
- Successfully passing the psychological and medical screening
- competent to sign informed consent
- Slovenian social insurance
- English language fluency
Exclusion Criteria:
- Medication required that may interfere with the interpretation of the results
- Bone mineral density (as measured by DEXA) more than 1.5 standard deviations < t score
- Recent sub-standard nutritional status
- Family history of thrombosis or positive response in thrombosis screening procedure.
(Biochemical analysis of the following parameters: ATIII, High sensitive C-reactive protein, S-Akt., Factor V-Leiden, Prothrombin, Lupus-partial thromboplastin time, Factor II)
- History of: thyroid dysfunction, renal stones, diabetes, allergies, hypertension, hypocalcemia, uric acidaemia, lipidaemia, or hyperhomocysteinaemia
- Gastro-esophageal reflux disease or renal function disorder, Hiatus hernia
- History of medical illness
- Smoker within six months prior to the start of the study
- Abuse of drugs, medicine or alcohol
- Participation in another study up to two months before study onset
- No signed consent form before the onset of the experiment
- Blood donors in the past three months before the onset of the experiment
- Vegetarian and Vegans
- Migraines
- History of orthostatic intolerance
- History of vestibular disorders
- Claustrophobia
- metallic implants, osteosynthesis material
- Chronic back pain
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Hypoxic ambulatory
Participants ambulatory in normobaric hypoxia with standardised nutritional intake
|
21 days confinement in normobaric hypoxic (FiO2 = 14%)
Participants hava a standardized activity level throughout the intervention
Macronutrient, salt and dietary energy intake will be standardized per kg body weight for each participant
|
EXPERIMENTAL: Hypoxic Bed rest
Participants are on bed rest in normobaric hypoxia with standardised nutritional intake
|
21 days confinement in normobaric hypoxic (FiO2 = 14%)
Macronutrient, salt and dietary energy intake will be standardized per kg body weight for each participant
Participants remain on supine bed rest throughout the intervention
|
ACTIVE_COMPARATOR: Normoxic bed rest
Participants are on bed rest in normobaric normoxia with standardised nutritional intake
|
Macronutrient, salt and dietary energy intake will be standardized per kg body weight for each participant
Participants remain on supine bed rest throughout the intervention
21 days confinement in normobaric normoxic (FiO2 = 21%) environment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in bone mineral content, from baseline
Time Frame: 40 days
|
assessed before (day -5), on days 2, 10 and 21 of the intervention and at the 14-day follow-up visit (40 days after 1st measurement) using pQCT scans of the calf and thigh.
|
40 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in urinary calcium concentration, from baseline
Time Frame: 30 days
|
assessed from 24hr urine collections taken before (day -5), on days 1,2,3,4,8,10,12,14,16,18, and 21 of the intervention and on the 2nd, 3rd, and 4th day after each intervention period (last urine collection 30 days after first measurement)
|
30 days
|
Change in urinary phosphate concentration, from baseline
Time Frame: 31 days
|
assessed from 24hr urine collections taken before (day -5), on days 1,2,3,4,8,10,12,14,16,18, and 21 of the intervention and on the 2nd, 3rd, and 4th day after each intervention period (last urine collection 31 days after first measurement)
|
31 days
|
Change in urinary N-terminal telopeptide concentration, from baseline
Time Frame: 31 days
|
assessed from 24hr urine collections taken before (day -5), on days 1,2,3,4,8,10,12,14,16,18, and 21 of the intervention and on the 2nd, 3rd, and 4th day after each intervention period (last urine collection 31 days after first measurement)
|
31 days
|
Change in fasting serum calcium concentration, from baseline
Time Frame: 26 days
|
assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention.
Last sample point made 26 days after baseline sample
|
26 days
|
Change in fasting serum phosphate concentration, from baseline
Time Frame: 26 days
|
assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention.
Last sample point made 26 days after baseline sample
|
26 days
|
Change in fasting serum bone specific alkaline phosphatase concentration, from baseline
Time Frame: 26 days
|
assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention.
Last sample point made 26 days after baseline sample
|
26 days
|
Change in fasting serum parathyroid hormone concentration, from baseline
Time Frame: 26 days
|
assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention.
Last sample point made 26 days after baseline sample
|
26 days
|
Change in fasting serum 25-Hydroxyvitamin D concentration, from baseline
Time Frame: 26 days
|
assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention.
Last sample point made 26 days after baseline sample
|
26 days
|
Change in fasting serum Procollagen-I-N-terminal propeptide concentration, from baseline
Time Frame: 26 days
|
assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention.
Last sample point made 26 days after baseline sample
|
26 days
|
Change in fasting serum Dickkopf-related protein 1 concentration, from baseline
Time Frame: 26 days
|
assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention.
Last sample point made 26 days after baseline sample
|
26 days
|
Change in fasting serum Sclerostin concentration, from baseline
Time Frame: 26 days
|
assessed from venous blood samples taken before (day -5), and on days 2,5,10,14 and 21 of each intervention.
Last sample point made 26 days after baseline sample
|
26 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Igor Mekjavic, PhD, Jozef Stefan Institute
- Principal Investigator: Jörn Rittweger, MD, PhD, German Aerospace Center (DLR)
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 284438/WP3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypoxia
-
Western University, CanadaUnknownBrain Hypoxia IschemiaCanada
-
Yale UniversityTianjin Chest HospitalCompletedBrain Ischemia Hypoxia | Muscle; Ischemic | Muscle HypoxiaChina
-
Fliegerärztliches InstitutCompleted
-
University of Texas at AustinCompletedIntermittent HypoxiaUnited States
-
Owlet Baby Care, Inc.Completed
-
Robert L. OwensCompletedIntermittent HypoxiaUnited States
-
Montreal Heart InstituteUniversité de MontréalCompleted
-
United States Army Research Institute of Environmental...University of Puget SoundRecruiting
-
The University of Hong Kong-Shenzhen HospitalRecruiting
-
Sherief Abd-ElsalamRecruiting
Clinical Trials on Hypoxia
-
Shirley Ryan AbilityLabEdward Hines Jr. VA HospitalCompletedMultiple Sclerosis, Relapsing-RemittingUnited States
-
Indiana UniversityRehabilitation Hospital of IndianaRecruitingBrain InjuriesUnited States
-
Charite University, Berlin, GermanyCompleted
-
Capital Medical UniversityRecruiting
-
University Hospital, GrenobleAgir pour les maladies chroniquesNot yet recruitingStroke, Ischemic | Stroke SequelaeFrance
-
Northwestern UniversityRecruitingHealthy Brain PerfusionUnited States
-
Shirley Ryan AbilityLabUnknownSpinal Cord InjuriesUnited States
-
University of Colorado, BoulderMedical University of South Carolina; University of Colorado, Denver; Eunice...Enrolling by invitationIncomplete Spinal Cord InjuryUnited States
-
Shirley Ryan AbilityLabEnrolling by invitation
-
Poznan University of Physical EducationCompleted